[Clinical trial of treatment of laryngeal cancer by recombinant adenovirus p53 combined with chemotherapy].
OBJECTIVE
To evaluate the effectiveness of recombinant adenovirus p53 injection (rAd2p53) combined with cisplatin plus 5-fluorouracil regimen in treating laryngeal carcinoma.


METHODS
Tumour animal models were established in the back of mice with Hep-2 cell line. Recombinant adenovirus p53 injection (rAd2p53) were transduced to tumor-bearing mouse by direct intratumoral injection combine with cisplatin plus 5-fluorouracil ivgtt. The control group 1 was given recombinant adenovirus p53 injection (rAd2p53) simplex. The control group 2 was administered with cisplatin plus 5-fluorouracil ivgtt simplex. Then compare the diameters of pro-treatment with that of post-treatment and test group with controls.


RESULTS
Tumor growth was significantly inhibited following combined rAd2p53 gene therapy with cisplatin plus 5-fluorouracil chemotherapy compared to single rAd2p53 gene therapy and cisplatin plus 5-fluorouracil chemotherapy controls.


CONCLUSIONS
Local injection of rAd2p53 combined with cisplatin plus 5-fluorouracil chemotherapy is a promising treatment to laryngeal cancer.
Dou
Xiaohui
X
Department of Otolaryngology, People's Hospital of Zhuhai, Zhuhai, 519000, China. douxiaohui66@hotmail.com
Zhao
Xiaoming
X
Wang
Yanqun
Y
Zeng
Liang
L
Wang
Zhiwei
Z
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D016158:Genes, p53; D015316:Genetic Therapy; D005822:Genetic Vectors; D007822:Laryngeal Neoplasms / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental